FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compounds of formula I and its pharmaceutically acceptable salts. In formula (I) , R stands for 6-unit ring, containing one ore two heteroatoms of nitrogen, and substituted with group selected from the following groups: (lower)alkyl, -C(O)-R1, (lower)alkyl, substituted with group -SO2-(lower)alkyl, (lower)alkyl, substituted with group -C(O)-R1, -SO2-(lower)alkyl, or 5-unit saturated ring, containing one heteroatom of nitrogen, R1 is selected from group, including (lower)alkyl, -N((lower)alkyl)2, or R1 stands for 6-unit saturated ring, containing two heteroatoms, selected from N and O, X1 and X2 are independently selected from group, including hydrogen, (lower)alkoxy, each Y1 and Y2 are independently selected from group, including -Cl and -Br, and absolute stoichiometric configuration in position 4 and 5 imidazoline ring includes S and R configuration, accordingly. Invention also relates to pharmaceutical composition, having inhibiting activity regarding interaction of MDM2 - p-53, containing efficient amount of invention compound.
EFFECT: production of compounds, having inhibiting activity as regards interaction of MDM2-p-53.
12 cl, 17 ex
Title | Year | Author | Number |
---|---|---|---|
DERIVANTS OF 2, 4, 5-TRIPHENYLIMIDAZOLINE AS INACTIVATORS OF INTERACTION BETWEEN P53 AND MDM2 PROTEINS DESIGNED FOR APPLICATION AS ANTICANCER DRUGS | 2006 |
|
RU2442779C2 |
CIS-2,4,5-TRIARYLIMIDAZOLINES AND USE THEREOF AS ANTICANCER MEDICINAL AGENTS | 2006 |
|
RU2411238C2 |
CIS-2,4,5-TRIPHENYLIMIDAZOLINES AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2002 |
|
RU2305095C2 |
CIS-IMIDAZOLINES AS MDM2 INHIBITORS | 2004 |
|
RU2354649C2 |
CHIRAL CIS-IMIDAZOLINES | 2008 |
|
RU2487127C2 |
NEW DISPIRO-INDOLINONES, MDM2/p53 INTERACTION INHIBITORS, METHOD FOR PRODUCTION AND APPLICATION | 2015 |
|
RU2629750C2 |
SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | 2009 |
|
RU2506257C2 |
DISPIROINDOLINONES BASED ON RHODANINES AS P53-MDM2 INHIBITORS OF PROTEIN-PROTEIN INTERACTION | 2019 |
|
RU2730286C1 |
METHOD OF OBTAINING DISPIROINDOLINONES | 2018 |
|
RU2682678C1 |
NK1/NK3 DOUBLE AGONISTS FOR TREATING SCHIZOPHRENIA | 2004 |
|
RU2347777C2 |
Authors
Dates
2011-01-10—Published
2005-06-08—Filed